Cosmo Pharmaceuticals N.V. Stock price

Equities

COPN

NL0011832936

Pharmaceuticals

Market Closed - Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
71.3 CHF +2.00% Intraday chart for Cosmo Pharmaceuticals N.V. +12.28% +40.08%

Financials

Sales 2023 96.72M 105M 94.31M Sales 2024 * 233M 252M 227M Capitalization 1.15B 1.24B 1.12B
Net income 2023 1M 1.08M 975K Net income 2024 * 111M 120M 108M EV / Sales 2023 9.1 x
Net cash position 2023 * 71.24M 77.03M 69.46M Net cash position 2024 * 110M 119M 107M EV / Sales 2024 * 4.45 x
P/E ratio 2023
771 x
P/E ratio 2024 *
9.8 x
Employees 319
Yield 2023 *
1.5%
Yield 2024 *
2.94%
Free-Float 44.7%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Cosmo Pharmaceuticals N.V.

1 day-0.07%
1 week+10.24%
Current month+6.22%
1 month+6.22%
3 months+36.45%
6 months+71.78%
Current year+37.52%
More quotes
1 week
62.50
Extreme 62.5
71.00
1 month
60.40
Extreme 60.4
71.90
Current year
51.20
Extreme 51.2
71.90
1 year
33.70
Extreme 33.7
71.90
3 years
33.70
Extreme 33.7
92.80
5 years
33.70
Extreme 33.7
103.00
10 years
33.70
Extreme 33.7
193.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 05-12-31
Director of Finance/CFO 52 16-05-31
Chief Tech/Sci/R&D Officer 54 -
Members of the board TitleAgeSince
Director/Board Member 57 21-05-27
Founder 69 96-12-31
Director/Board Member 64 05-12-31
More insiders
Date Price Change Volume
24-03-28 71.3 +2.00% 27 825
24-03-27 69.9 +7.54% 80,766
24-03-26 65 -2.40% 22,291
24-03-25 66.6 +0.76% 18,793
24-03-22 66.1 +4.09% 36,057

Delayed Quote Swiss Exchange, March 28, 2024 at 09:47 am EDT

More quotes
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
71.35 EUR
Average target price
95.67 EUR
Spread / Average Target
+34.08%
Consensus
  1. Stock
  2. Equities
  3. Stock Cosmo Pharmaceuticals N.V. - Swiss Exchange